Register for OBR daily


IMS_White_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

GALT $11.61 1.3300 +12.94%
PVCT $2.32 0.2100 +9.95%
SRNE $10.55 0.9000 +9.33%
AMBI $6.94 0.5300 +8.27%
CYTR $3.23 0.2300 +7.67%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

INO $2.52 -0.1500 -5.62%
THLD $3.83 -0.1900 -4.73%
INFI $10.15 -0.4500 -4.25%
NYMX $5.04 -0.2199 -4.18%
KPTI $31.09 -1.3100 -4.04%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

Puma Drug Better Than Herceptin in HER2 Breast Cancers: Trial

(Reuters) Apr 7, 2014 - A mid-stage trial of Puma Biotechnology's experimental drug neratinib showed that it was more effective, given before surgery, than Herceptin, the Roche drug commonly used in women with a type of breast cancer fueled by a protein called HER2.
read article 



Pfizer, Lilly Drugs Slow Advanced Breast Cancer in Studies

(Washington Post/Bloomberg) Apr 6, 2014 - Experimental breast cancer drugs from Pfizer and Eli Lilly slowed or halted the growth of advanced tumors in studies, potentially adding a new treatment option for patients and top-selling therapies for the companies.
read article (free registration required) 



Strong Tumor Response Seen From Agios Pharma Cancer Metabolism Drug

(TheStreet) Apr 6, 2014 - The Agios Pharmaceuticals cancer metabolism drug AG-221 is demonstrating surprisingly strong clinical activity, including multiple complete remissions, in an early stage study involving patients with advanced blood cancers.
read article 



Roche Buys Rights to Oryzon's Cancer-Suppressing Gene Drug

(Reuters) Apr 7, 2014 - Roche has bought the rights to an experimental drug from Spain's Oryzon Genomics that can switch on genes to block cancer growth, as the Swiss drugmaker looks to maintain its dominance in the lucrative field of oncology.
read article 



IMS Health Raises $1.3B in 2014's Second-Biggest IPO

(VentureBeat) Apr 4, 2014 - Health care information company IMS Health has a lot of new cash in its war chest.
read article 



E-Cig Rule Coming 'Very Soon,' U.S. FDA Chief Says

(Reuters) Apr 3, 2014 - The U.S. Food and Drug Administration is "pushing very hard" to release a proposed rule that would establish its authority over e-cigarettes, the head of the agency said on Thursday amid concerns the products pose a risk to children.
read article 



COA 2014 Community Oncology Kicks Off in Orlando, Florida

(COA) Apr 4, 2014 - Today, 500 members of the cancer community, including oncologists, nurses, pharmacists, administrators, patients/caregivers/survivors, industry representatives, and other members of the cancer care team, gather in Orlando to attend the Community Oncology Conference.
read article 



AbbVie Drops EU Court Bid to Block Clinical-Trial Data Release

(Bloomberg) Apr 3, 2014 - AbbVie Inc. dropped its European Union court challenges to block the European Medicines Agency from releasing clinical-trial data from the company.
read article 



Meda Rejects Mylan Approach

(Wall Street Journal) Apr 4, 2014 - Swedish specialty pharmaceuticals company Meda AB said Friday it rejected an indicative proposal from U.S. generic drug group Mylan Inc. to combine the two businesses.
read article (paid subscription required) 



A 'Rescue Pen' for Opioid Overdose Gets FDA's Blessing

(Los Angeles Times/Science Now) Apr 3, 2014 - Opioid drug overdoses, the cause of some 16,000 fatalities and half a million emergency-department visits yearly, may have met their match: The Food and Drug Administration on Thursday approved the sale, by prescription, of a hand-held auto-injector of the opioid-reversal drug naloxone, a "rescue pen" that caregivers or family members can use to avert a potentially fatal overdose.
read article (free registration required) 



Proposed Health IT Strategy Aims to Promote Innovation, Protect Patients, and Avoid Regulatory Duplication

(FDA) Apr 3, 2014 - HHS today released a draft report that includes a proposed strategy and recommendations for a health information technology (health IT) framework, which promotes product innovation while maintaining appropriate patient protections and avoiding regulatory duplication.
read press release 



Surprise Medical Bills Lead to Protection Laws: Health

(Bloomberg) Apr 4, 2014 - Hospital patients in New York are the latest in the nation to gain legal protection against unexpected bills from doctors who won’t accept their insurance.
read article 



Bayer to Present New Data on Advancing Oncology Portfolio

(Bayer) Apr 4, 2014 - Bayer HealthCare will present latest preclinical and clinical data on promising early-stage compounds with new mechanism of action at the American Association for Cancer Research (AACR) 105th Annual Meeting, April 5-9, 2014, in San Diego, CA.
read corporate press release 



Steiner Resigns From GTx

(Memphis Business Journal) Apr 4, 2014 - Mitch Steiner, CEO and co-founder of GTx Inc., has resigned, effective yesterday.
read article 



Dr. David Botstein Honored With 2014 American Association for Cancer Research-Irving Weinstein Foundation Distinguished Lectureship

(AACR) Apr 3, 2014 - The American Association for Cancer Research (AACR) will award David Botstein, Ph.D., with the 10th annual AACR-Irving Weinstein Foundation Distinguished Lectureship at the AACR Annual Meeting 2014, to be held in San Diego, Calif., April 5-9.
read press release 



American Association for Cancer Research-G.H.A. Clowes Memorial Award to Recognize Dr. James Allison

(AACR) Apr 3, 2014 - James P. Allison, Ph.D., will be recognized with the 54th annual American Association for Cancer Research (AACR) G.H.A. Clowes Memorial Award at the AACR Annual Meeting 2014, to be held in San Diego, Calif., April 5-9.
read press release 



AACR to Host Tobacco Control Session, Media Availability at Annual Meeting 2014

(AACR) Apr 4, 2014 - Leaders in the field of tobacco research will address the media on current tobacco control efforts in Room 15B of the San Diego Convention Center, 9 a.m. PT, Monday, April 7, as part of the American Association for Cancer Research (AACR) Annual Meeting 2014, held here April 5-9.
read press release 



ASCO Urges FDA to Require Tobacco Companies to Reduce Harmfulness of Cigarettes

(ASCO in Action) Apr 3, 2014 - ASCO joined 33 other leading health groups in sending a letter to Mitchell Zeller, J.D., Director of the Food and Drug Administration (FDA) Center for Tobacco Products, urging the agency to require tobacco companies to reduce the harmfulness and addictiveness of cigarettes.
read article 



Scott Walker Signs Chemotherapy Drugs Bill at Froedtert

(Milwaukee Journal Sentinel) Apr 3, 2014 - Gov. Scott Walker signed legislation Thursday easing costs for cancer patients in critical need of chemotherapy pills — a measure that appeared unlikely to get to him just a month ago.
read article 



Prime Therapeutics Study Finds Members Using Its Specialty Pharmacy More Likely to Stay on Medicines Than Those Filling Prescriptions at Retail Pharmacies

(Yahoo! Finance) Apr 3, 2014 - Receiving specialty drugs through Prime Therapeutics Specialty Pharmacy LLC rather than a retail pharmacy store is associated with improved adherence to these medicines, according to a new study by Prime Therapeutics LLC.
read article 



Federal Act Named for Gabriella Miller Signed Into Law

(Washington Post) Apr 3, 2014 - Less than six months after 10-year-old childhood cancer awareness advocate Gabriella Miller died of an inoperable brain tumor, a federal pediatric medical research bill named in her honor was signed into law by President Obama at a White House ceremony Thursday afternoon.
read article (free registration required) 



Cancer Genetics Announces Launch of CALR Mutation Analysis Test to Assist in Diagnosis of Acute Leukemias & Myeloproliferative Neoplasms

(MarketWatch) Apr 4, 2014 - New test launch extends CGI's leadership in genomic testing for blood cancers; CALR genetic mutation test will be a part of CGI's comprehensive focus on leukemia.
read article 



Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries

(TheStreet) Apr 4, 2014 - Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
read article 



Mylan Sues Celgene For Blocking Revlimid, Thalomid Generics

(Reuters) Apr 3, 2014 - Mylan Inc on Thursday sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.
read article 



Cancer Patients Face Treatment Disruptions Come June; Immediate and Severe Funding Cuts May Curtail Access to Cancer Clinical Trials

(ASCO) Apr 4, 2014 - The nation’s cancer clinical trial network, which provides care to thousands of patients across the United States, may have no choice but to abandon life-saving and life-extending research studies, including support for patients participating in those studies, due to crippling proposed budget cuts.
read press statement